Dr Craig Rayner

Craig is Senior Vice President, Integrated Drug Development at Certara Strategic Consulting. In this capacity he globally supports more than 140 PhD, MD and PharmD clinical and quantitative pharmacologists, pharmacometricans, scientists, regulatory science and drug development practitioners in creating value for clients across the drug development ecosystem, and ultimately medicine access to the patients they serve.

Prior to this role, Craig was the Co-founder and CEO of d3 Medicine until its acquisition in 2016 by Certara, then serving as President of d3 Medicine, a Certara company, until early 2018. d3 Medicine provided Strategic Planning and Stewardship of Complex Drug Development Programs.

Prior to d3 Medicine, Craig's past appointments included leadership roles in Clinical Pharmacology and Early development (Roche), Clinical development (CSL-Behring), in Business Development/Licensing as Global Due Diligence Director (Roche) and as an academic researcher in clinical pharmacology and infectious disease research (Monash University).

He has extensive experience in early and late development of therapeutics, regulatory interaction experience with all major global health authorities, multiple filings and accountability for numerous due diligences, active support of negotiations, deal making and integration activities.

Craig holds an Adjunct Associate Professorship in Pharmaceutical Science at Monash and is broadly published in clinical pharmacology and also infectious diseases.